New Zealand markets closed

Burning Rock Biotech Limited (BNR)

NasdaqGM - NasdaqGM Delayed price. Currency in USD
Add to watchlist
7.40-0.24 (-3.14%)
As of 04:00PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close7.64
Open7.69
Bid5.40 x 200
Ask9.98 x 200
Day's range7.15 - 7.69
52-week range5.72 - 26.20
Volume303
Avg. volume4,798
Market cap75.914M
Beta (5Y monthly)0.18
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Bayer and Burning Rock collaborate to increase patient access to precision cancer medicines

    GUANGZHOU, China, May 30, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”) has recently announced a collaboration with Bayer to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx), aiming to provide diagnostic methods, to enable treatment choice for patients with cancer in China, while driving innovation and development in cancer therapy. This collaboration will focus on the development of companion dia

  • GlobeNewswire

    Burning Rock Reports First Quarter 2024 Financial Results

    GUANGZHOU, China, May 29, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended March 31, 2024. Recent Business Updates Early Detection THUNDER study for 6-cancer test was included in the Diagnosis and Treatment Guidelines for Primary Liver Cancer (2024 Editi

  • GlobeNewswire

    Burning Rock Schedules First Quarter of 2024 Earnings Release on May 29, 2024

    GUANGZHOU, China, May 23, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it plans to release its unaudited financial results for the first quarter of 2024 before the U.S. market opens on May 29, 2024. Following the release, company management will host a conference call at 8:00 a.m. ET (8:0